Synlogic Inc Stock News
$1.41
0.71%
today
Nasdaq,
Sep 16, 08:32 pm CET
Synlogic Inc Stock News
Neutral
GlobeNewsWire
●
about one month ago
WINCHESTER, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the second quarter 2024 and provided a corporate update.
Negative
InvestorPlace
●
4 months ago
“Sell in May and go away” is a common adage in investing. It's based on the historical pattern of stocks underperforming from May to October when investors tend to stay on the sidelines.
Neutral
GlobeNewsWire
●
4 months ago
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the first quarter 2024 and provided a corporate update.
Neutral
GlobeNewsWire
●
6 months ago
CAMBRIDGE, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the fourth quarter and full year ending December 31, 2023.
Neutral
GlobeNewsWire
●
7 months ago
Engages Ladenburg Thalmann as financial advisor to assist with previously announced strategic review process Engages Ladenburg Thalmann as financial advisor to assist with previously announced strategic review process
Negative
InvestorPlace
●
7 months ago
Synlogic (NASDAQ: SYBX ) stock is falling on Friday after the clinical-stage biopharmaceutical company announced the discontinuation of its Synpheny-3 clinical trial. According to a press release from Synlogic, this decision comes after an internal review of the clinical trial's progress.
Neutral
GlobeNewsWire
●
7 months ago
Decision to end trial follows internal review of initial data indicating study unlikely to meet primary endpoint Data review found treatment to be safe and well-tolerated Board of Directors plans to perform assessment of strategic options CAMBRIDGE, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the c...
Neutral
GlobeNewsWire
●
8 months ago
Findings support positive proof of mechanism, through successful degradation of methionine, precursor to homocysteine, using dietary disease model in preclinical models and healthy volunteer study
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
